VanEck’s Dividend Heavyweight Reaches €7.5 Billion as Cost Advantage Fuels Inflows and a June Rebalance Looms

VanEck's TDIV ETF reaches €7.5bn AUM, 20% total return but RSI at 84 signals overbought; top holdings Exxon and Pfizer reinforce dividend quality.

The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF has crossed the €7.5 billion mark in assets under management, a milestone that underscores the market’s appetite for high-quality dividend payers. A key driver behind its popularity is its expense ratio of 0.38% — well below the category average of 1.06%. Morningstar has awarded the fund its top rating, reflecting both efficiency and risk-adjusted performance. In the first quarter alone, TDIV attracted roughly €2.1 billion in net inflows, making it one of the best-selling products in its peer group during the strongest three-month period for dividend funds globally in four years.

That investor enthusiasm is visible in the price action. The ETF recently closed at €52.06, just shy of its 52-week high of €52.93, delivering a 12-month total return approaching 20%. However, the relative strength index has climbed to 84, flashing a clear overbought signal. The technical picture suggests near-term caution, even as the fundamental backdrop remains supportive.

TDIV’s construction is designed to sidestep yield traps. The underlying index selects the 100 strongest dividend payers from developed markets, applying strict guardrails: no stock may exceed a 5% weighting, sector exposure is capped at 40%, and every holding must show at least five years of uninterrupted or rising dividends. A payout ratio below 75% ensures sustainability. Currently, financials account for 31.58% of the portfolio, energy for 17.89%, and health care for 15.28%. The dividend growth trajectory has been solid, with an average increase of nearly 17% per annum over the past three years.

Two heavyweight positions illustrate why the fund fits its mandate. ExxonMobil, the top holding, is set to go ex-dividend on May 15 for its quarterly payout of $1.03 per share, with the payment arriving on June 10. The oil major has raised its dividend for 44 consecutive years. Meanwhile, Pfizer reported first-quarter adjusted earnings of $0.75 per share, about 4% above consensus, as core revenue (excluding Covid products) climbed 7% year on year to $14.5 billion. The pharmaceutical giant’s predictable cash flows reinforce the quality story TDIV aims to capture.

June will be a busy month for the ETF. The next distribution goes ex-dividend on June 4, with the payout scheduled for June 11. Over the past twelve months, total distributions have reached €1.74 per share. Also on the calendar is the semi-annual index rebalancing, which could see certain stocks replaced if they no longer meet the dividend-criteria or if sector limits are breached. The combination of a scheduled payment and a portfolio reshuffle makes early summer a pivotal period for the fund.

VanEck is simultaneously expanding its product lineup. On April 23, an Irish-domiciled variant, TDVX, began trading on the London Stock Exchange. Its mandate is straightforward: TDIV distributes income, while TDVX automatically reinvests it, targeting investors in jurisdictions where accumulating ETFs are preferred. The timing aligns with a broader trend — global dividend-oriented funds collected $24.1 billion in the first quarter, the strongest three-month haul in four years.

The near-term challenge for TDIV is to demonstrate that its dividend-driven strategy can sustain momentum despite elevated valuations. The overbought RSI combined with a dense calendar of corporate and index events means the ETF must prove that the inflows are backed by durable income, not simply yield-chasing. Given the strict filters, a cost advantage that is less than half the category norm, and a proven track record of payout growth, the odds appear tilted in its favour — but the next few weeks will put that thesis to the test.